Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Clinical Pharmacology and Therapeutics|April 23, 2010
A pharmacometric model describing the relationship between warfarin dose and INR response with respect to variations in CYP2C9, VKORC1, and ageA-K Hamberg, M Wadelius, J D Lindh, et al.
The Pharmacogenomics Journal|May 11, 2005
Common VKORC1 and GGCX polymorphisms associated with warfarin doseM Wadelius, L Y Chen, K Downes, et al.
Pharmacogenetics|September 2, 1999
Polymorphisms in NAT2, CYP2D6, CYP2C19 and GSTP1 and their association with prostate cancerM Wadelius, J L Autrup, M J Stubbins, et al.
The Pharmacogenomics Journal|June 9, 2016
Cost-effectiveness of pharmacogenetic-guided dosing of warfarin in the United Kingdom and SwedenT I Verhoef, W K Redekop, S Langenskiold, et al.
Clinical Pharmacology and Therapeutics|June 20, 2014
Patients benefit from genetics-guided coumarin anticoagulant therapyA H Maitland-van der Zee, A K Daly, F Kamali, et al.
Clinical Pharmacology and Therapeutics|September 9, 2011
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosingJ A Johnson, L Gong, M Whirl-Carrillo, et al.
Clinical Pharmacology and Therapeutics|May 24, 2012
The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathyR A Wilke, L B Ramsey, S G Johnson, et al.
Clinical Pharmacology and Therapeutics|June 25, 2014
Phenotype standardization of angioedema in the head and neck region caused by agents acting on the angiotensin systemM Wadelius, S E Marshall, G Islander, et al.
The Pharmacogenomics Journal|April 9, 2014
The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysisM M Dias, J-P Pignon, C S Karapetis, et al.
Clinical Pharmacology and Therapeutics|June 5, 2014
Phenotype standardization for statin-induced myotoxicityA Alfirevic, D Neely, J Armitage, et al.
Pageof 3